Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acepodia, Adagene, Adaptive, Alphamab Oncology, Astrazeneca, Atum, Biocryst, Bold, Canbridge, Catalent, Celltrion, Chelation, Chrysalis, Debiopharm, Dr. Reddy's, Dyadic, Egle, Emergent, Fujifilm, Gilead, Grifols, Innovation, Intas, Izana, Johnson & Johnson, Kalytera, Leading, Lyvgen, Merck, Microsoft, Mitsubishi Tanabe, Mymetics, Naari, Oblique, Oncolys, Orgenesis, Panacea, Pharmabcine, Pharmamar, Phylex, Qualigen, Refana, Regeneron, Sanofi, Serimmune, Takeda, Thermo Fisher Scientific, Thermogenesis, Transposon, TTY Biopharm, Twist, Vault.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Albireo, Appili, JW Therapeutics (Shanghai) Co., Immvira, Shattuck Labs, Takeda.
New hires and promotions in the biopharma industry in Asia-Pacific, including: Canbridge Pharmaceuticals.
The latest global regulatory news, changes and updates affecting biopharma, including: Department of Defense, FDA, Minister of Health, National Center for Advancing Translational Sciences, NIH.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Atyr, Can-Fite, Eli Lilly, Humanigen, Immunic, Kyowa Kirin, Moderna, Neurorx, Oncoimmune, Opko Health, Opthea, Orpheris, Otsuka, Pluristem, Regeneron, Relief, Sinovac, Solasia, Tychan.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Biophytis, Diffusion, Fulcrum, Genequantum, Immune, Immunic, Immuron, Redhill, Revive.